Former Head of Global Government Affairs and Policy at Gilead
Sciences led wide-ranging collaborations with leading academic
institutions and non-profit groups
SAN DIEGO –
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced the appointment of industry leader David Gollaher, Ph.D., to
the company’s Board of Directors.
“With more than 30 years of experience in the biopharma and healthcare
industry, Dr. Gollaher is an outstanding addition to our Board,” said
Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
“Dr. Gollaher has an impressive track record and brings a wealth of
experience in government affairs and health policy, having established a
wide range of collaborations and relationships with leading academic
institutions and non-profit groups while at Gilead and throughout his
career. We welcome his insights as we continue to advance our pipeline
to deliver novel anti-infectives to patients and providers.”
“I’m honored to join Cidara’s board of directors at an exciting moment
as the company moves into late-stage clinical development,” said David
Gollaher, Ph.D. “Cidara’s pipeline holds great promise for treating and
preventing serious infections and, led by an experienced and highly
capable management team, the company is well positioned to bring value
to patients, providers and investors. It’s a privilege to join them on
the path toward medical and commercial success.”
Dr. Gollaher served as vice president of worldwide government affairs
and policy for Gilead Sciences from early 2014 to mid-2018, a period
during which the company launched a breakthrough cure for the hepatitis
C virus (HCV) and tripled revenues from $10 billion to $30 billion. In
addition to leading the introduction of three novel drugs for HCV,
building on Gilead’s strength in virology, he was involved in the launch
of a new generation of medicines for HIV/AIDS. Prior to joining Gilead,
Dr. Gollaher served for 20 years as co-founder and chief executive
officer of the California Healthcare Institute (CHI). During this time,
he built CHI into the nation’s premier state-based life sciences policy
research and advocacy association, representing nearly 370 biopharma,
medical device and diagnostics companies, along with leading academic
institutions, venture capital and professional services firms. Earlier
in his career, Dr. Gollaher was vice president at Scripps Clinic and
Research Foundation, responsible for managed care, strategy and
corporate affairs.
Additionally, in June of 2018, Dr. Gollaher was appointed a Senior
Fellow at the Leonard D. Schaeffer Center for Health Policy and
Economics at the University of Southern California. He also currently
serves on Gilead’s Health Policy Advisory Board and the Board of
Overseers for The Scripps Research Institute. He earned a Bachelor of
Arts degree from University of California Santa Barbara and both masters
and doctorate degrees from Harvard University.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing
new anti-infectives that have the potential to transform the standard of
care and save or improve patients’ lives. The company is currently
advancing its novel echinocandin antifungal, rezafungin acetate,
formerly known as CD101 IV, through clinical trials. Rezafungin has
improved pharmacokinetics compared to existing echinocandins and the
potential for expanded utility across patient settings. It is the only
once-weekly product candidate in development for the treatment and
prevention of life-threatening invasive fungal infections. The company’s
Phase 2 STRIVE clinical trial of rezafungin met its primary safety and
efficacy objectives, and provides support for Cidara to initiate Phase 3
pivotal trials in the treatment of candidemia and invasive candidiasis
and the prophylaxis of invasive fungal infections. Cidara also is
leveraging its novel Cloudbreak™ platform to develop antibody-drug
conjugates for the treatment of multi-drug resistant Gram-negative
bacterial infections. Cloudbreak is the first immunotherapy discovery
platform designed specifically to create compounds that directly kill
pathogens and also direct a patient’s immune cells to attack and
eliminate bacterial, fungal or viral pathogens. Cidara is headquartered
in San Diego, California. For more information, please visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are
not historical facts are “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, the impact of Dr. Gollaher’s appointment to Cidara’s board of
directors and our ability to advance our pipeline to deliver novel
anti-infectives to patients and providers, the potential for the
expanded utility of rezafungin across patient settings, and Cidara’s
ability to successfully complete development of rezafungin and receive
regulatory approval for any indication. Risks that contribute to the
uncertain nature of the forward-looking statements include: the success
and timing of Cidara’s preclinical studies and clinical trials;
regulatory developments in the United States and foreign countries;
changes in Cidara’s plans to develop and commercialize its product
candidates; Cidara’s ability to obtain additional financing; Cidara’s
ability to obtain and maintain intellectual property protection for its
product candidates; and the loss of key scientific or management
personnel. These and other risks and uncertainties are described more
fully in Cidara’s Form 10-Q most recently filed with the United States
Securities and Exchange Commission. All forward-looking statements
contained in this press release speak only as of the date on which they
were made. Cidara undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the date on
which they were made.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180912005164/en/
INVESTOR CONTACT:
Westwicke Partners, LLC
Robert H. Uhl
Managing
Director
858-356-5932
robert.uhl@westwicke.com
or
MEDIA
CONTACT:
Sam Brown Inc.
Christy Curran
615-414-8668
ChristyCurran@sambrown.com
